PARP抑制剂
医学
聚ADP核糖聚合酶
奥拉帕尼
前列腺癌
肿瘤科
人口
内科学
癌症
聚合酶
癌症研究
生物
DNA
遗传学
环境卫生
作者
Mark J. O’Connor,Josep V. Forment
标识
DOI:10.1007/978-3-031-30065-3_3
摘要
Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) represent the first medicines based on the targeting of the DNA damage response (DDR). PARPi have become standard of care for first-line maintenance treatment in ovarian cancer and have also been approved in other cancer indications including breast, pancreatic and prostate. Despite their efficacy, resistance to PARPi has been reported clinically and represents a growing patient population with unmet clinical need. Here, we describe the various mechanisms of PARPi resistance that have been identified in pre-clinical models and in the clinic.
科研通智能强力驱动
Strongly Powered by AbleSci AI